Alzheimer Disease Clinical Trial
Official title:
Repetitive Transcranial Magnetic Stimulation With H-coil in Alzheimer's Disease: A Double-blind, Placebo-controlled Pilot Study
Verified date | September 2020 |
Source | IRCCS San Raffaele |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Focal repetitive transcranial magnetic stimulation (rTMS) has been applied to improve cognition in Alzheimer's disease (AD) with conflicting results. In this study we aimed to explore feasibility, safety and efficacy of excitatory rTMS of bilateral DLPFC applied with H-coil in AD in a pilot randomized, placebo-controlled, double-blind study.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 8, 2014 |
Est. primary completion date | September 8, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Ability to understand the purpose and risk of the study and provide signed and dated informed consent. - Male or female subjects, 18 to 80 years old. - Diagnosis of Alzheimer's disease according to the DSM IV - Subjects who answered all questions in the TMS pre-treatment safety questionnaire in a negative manner. - Have given written informed consent Exclusion Criteria: - Presence of an additional neurological or psychiatric pathology. - Severe personality disorder. - Uncontrolled hypertension. - History of epilepsy, seizures, febrile convulsions. - History of epilepsy or seizures in first degree relatives. - History of head injury or stroke. - Presence of metal prostheses in the head (except dental fillings). - Metal implants or known history of any metal particles in the eye, cardiac pacemakers, cochlear implants, use of neurostimulators or medical pumps. - History of migraine within the past six months. - History of drug or alcohol abuse. - Impossibility of adequate communication with the examiner. - Participation in another clinical study, either concomitant or within the previous 3 months. - Inability to sign the consent form. |
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS San Raffaele | Milan | MI |
Lead Sponsor | Collaborator |
---|---|
Giancarlo Comi |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement at Alzheimer's Disease Assessment Scale-cognitive over time | Brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia | Change in the score between Baseline evaluation and end of the treatment (2 months after start of the treatment) | |
Secondary | Improvement at Mini Mental State Examination scale over time | Neuropsychological test used to assess the intellectual efficiency disorders and the presence of cognitive impairment | Baseline evaluation, 1 month after start of the treatment, end of the treatment (2 months after start of the treatment) and end of follow-up (4 months after start of the treatment) | |
Secondary | Improvement at Beck Depression Inventory scale-II over time | Self-report inventory, psychometric test used to assess the severity of depression | Baseline evaluation, 1 month after start of the treatment, end of the treatment (2 months after start of the treatment) and end of follow-up (4 months after start of the treatment) | |
Secondary | Improvement at Clinical Global Impression-Improvement scale over time | Scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention | Baseline evaluation, 1 month after start of the treatment, end of the treatment (2 months after start of the treatment) and end of follow-up (4 months after start of the treatment) | |
Secondary | Persistence of improvement at Alzheimer's Disease Assessment Scale-cognitive over time | Brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia | Change in the score between end of treatment (2 months after start of the treatment) and end of follow-up (4 months after start of treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |